Examples of 'a-synuclein' in a sentence
Meaning of "a-synuclein"
a-synuclein (noun) - A protein found in the human brain that is associated with various neurodegenerative diseases, including Parkinson's disease. It plays a role in regulating the release of neurotransmitters and maintaining the integrity of synapses
How to use "a-synuclein" in a sentence
Basic
Advanced
a-synuclein
The invention uses various forms of a-synuclein.
Human and mouse a-synuclein are highly conserved proteins.
One shared node is the involvement of a-synuclein.
Intraneuronal a-synuclein aggregates in the contralateral side are circled.
Immunostaining was performed with a polyclonal antibody for a-synuclein.
An in vitro method of detecting a-synuclein protofibrils, comprising the steps of.
A-synuclein aggregates by different compounds.
Fragments can also be combined with full length a-synuclein.
Clearance of a-synuclein protofibrils in the brain is of significant clinical value.
Expression of aggregated form of a-synuclein.
Different a-synuclein forms including protofibrils and fibrils, are in equilibrium.
These results emphasize the relevance of a-synuclein to the study of neurodegeneration.
Differences in a-synuclein expression patterns are observed depending of differentiation protocol.
It is not completely known how the a-synuclein aggregation cascade begins.
This finding shows that the compound is able to inhibit aggregation of a-synuclein.
See also
Toxic aggregates of a-synuclein disrupt the integrity of cell membranes.
In this way, it is possible to induce the formation of intracellular a-synuclein aggregates.
Antibodies that recognize a-synuclein protofibrils / oligomers are detected in the serum.
The present invention is based on the use of stabilized soluble oligomers of a-synuclein.
The pathogenic consequences of the a-synuclein mutations are only partly understood.
The invention is directed to antibodies that bind stabilised soluble a-synuclein oligomers.
Cells are analyzed for a-synuclein aggregation by immunoblot and confocal microscopy.
However, recent research suggests that oligomeric forms of a-synuclein are particularly neurotoxic.
A-synuclein protofibrils are considered highly neurotoxic, initiating and driving the disease process.
Optionally, either the antibody or a-synuclein target is immobilized in such assay.
It recognizes an epitope that includes the first three amino acids of a-synuclein.
It has previously been shown that tau and a-synuclein pathologies may be closely linked.
The a-synuclein aggregate counts for two sections were summed for each hemisphere.
These mice can be used for obtaining a-synuclein oligomeric-specific monoclonal antibodies.
In another embodiment, the antibodies and fragments exhibit low binding to a-synuclein fibrils.
Hybridomas were generated by injecting ONE-modified a-synuclein protofibrillar / oligomer preparations as previously described.
More specifically, the invention relates to antibodies which bind stabilised soluble a-synuclein.
Oligomers of a-synuclein and fragments thereof are usually soluble and exist predominantly as a-helices.
Mice are analyzed behaviorally, neuropathologically, and biochemically for a-synuclein aggregation and neurodegeneration.
However, these soluble a-synuclein forms are instable and polymerize spontaneously to insoluble fibrils.
The antibodies and fragments thereof exhibit high efficiency in clearance of pathogenic forms of a-synuclein.
Detecting the presence of a complex formed between a-synuclein protofibril and said antibody or fragment.
This model acts by inducing oxidative stress in transgenic mice with oligodendroglial a-synuclein expression.
The molecular mechanism by which a-synuclein self-association triggers cellular degeneration is at present largely unknown.
Another advantage is that the additional components will increase stability of a-synuclein protofibrils / oligomers.
Pathological aggregates of a-synuclein as exemplified by immunohistochemical staining described in Example 3.
Application of HDACIs to PD neurons blocks a-synuclein toxicity.
Summary of a-synuclein titers and immunoblot affinity ( corrected for titer ).
The primary protein aggregate in a Lewy body is composed of a-synuclein.
Several studies have implicated a-synuclein with a central role in PD pathogenesis.
Transgenic or other animal models of Lewy Body diseases can express a human a-synuclein transgene.
Human Antibodies Human antibodies against a-synuclein are provided by a variety of techniques described below.
As is known in the art, protofibrils are soluble oligomers of a-synuclein.
Furthermore, dopamine in the background of a-synuclein overexpression is toxic.
Figure 22 shows an exemplary expression of aggregated form of a-synuclein.
